The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cmax (Maximum Observed Concentration in Plasma) of MP-424
Timeframe: Data were collected at Day1 to Day85
Tmax (Time of Maximum Concentration in Plasma) of MP-424
Timeframe: Data were collected at Day1 to Day85
AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424
Timeframe: Data were collected at Day1 to Day85
Ctrough (Minimum Observed Concentration in Plasma) of MP-424
Timeframe: Data were collected at Day1 to Day85
T1/2(Time of Half-Life) of MP-424
Timeframe: Data were collected at Day1 to Day85